New cholinesterase inhibitors for Alzheimer's disease: Structure activity relationship, kinetics and molecular docking studies of 1–butanoyl–3–arylthiourea derivatives
作者:Fayaz Ali Larik、Muhammad Shakil Shah、Aamer Saeed、Hamid Saeed Shah、Pervaiz Ali Channar、Michael Bolte、Jamshed Iqbal
DOI:10.1016/j.ijbiomac.2018.05.001
日期:2018.9
most common symptoms may include loss of memory along with disturbed behavioral and cognitive functions. Until now, only 4 cholinesterase (ChE) inhibitors are approved by FDA for symptomatic treatment of AD. Aroyl thiourea derivatives are well known bioactive organic molecules containing carbonyl and thiocarbonyl functional groups. Here, total 14 different thiourea derivatives (3a-3n) were synthesized
高度进展的神经退行性疾病通常称为阿尔茨海默氏病(AD),是一种痴呆症,在老年人中非常常见。最常见的症状可能包括记忆力减退以及行为和认知功能受损。到目前为止,FDA仅批准了4种胆碱酯酶(ChE)抑制剂用于AD的对症治疗。芳酰基硫脲衍生物是众所周知的含有羰基和硫代羰基官能团的生物活性有机分子。在这里,总共合成了14种不同的硫脲衍生物(3a-3n),并通过NMR,FTIR和X射线晶体学技术对其进行了表征。合成的化合物对乙酰胆碱酯酶(AChE)和丁酰胆碱酯酶(BuChE)酶均表现出不同的抑制活性。在所有化合物中,3b和3e是AChE的有效抑制剂(IC50±SEM = 8.92±1。03μM)和BuChE(IC50±SEM = 6.96±0.961μM)。酶动力学研究表明3b与AChE竞争性结合,而3e对BuChE具有混合抑制作用。AChE的分子对接研究表明3b与BuChE对接时,3b与Trp86和